LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Uždarymo kaina

14.36 -0.55

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.02

Max

14.41

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -18M
Pelnas, tenkantis vienai akcijai	-0.29
Darbuotojai	54
EBITDA	-1.5M -20M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+16.92% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	175M 975M
Ankstesnė atidarymo kaina	14.91
Ankstesnė uždarymo kaina	14.36

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-15 22:47; UTC

Karštos akcijos

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

2026-05-15 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

2026-05-15 22:00; UTC

Pagrindinės rinkos jėgos

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

2026-05-15 18:09; UTC

Pagrindinės rinkos jėgos

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

2026-05-15 16:02; UTC

Uždarbis

Pagrindinės rinkos jėgos

Forward Industries Shares Fall on New Debt as Solana Value Drops

2026-05-15 14:55; UTC

Pagrindinės rinkos jėgos

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

2026-05-15 14:43; UTC

Pagrindinės rinkos jėgos

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

2026-05-15 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

2026-05-15 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

2026-05-15 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

2026-05-15 21:16; UTC

Rinkos pokalbiai

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 20:19; UTC

Karštos akcijos

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

2026-05-15 19:41; UTC

Įsigijimai, susijungimai, perėmimai

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

2026-05-15 19:35; UTC

Rinkos pokalbiai

Oil Futures Settle Higher on Inventory Worries -- Market Talk

2026-05-15 19:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

2026-05-15 18:35; UTC

Uždarbis

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026-05-15 17:28; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

2026-05-15 16:50; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

2026-05-15 16:24; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

2026-05-15 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-15 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-15 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-15 15:55; UTC

Rinkos pokalbiai

Canada's 1Q Rebound Not a Turning Point -- Market Talk

2026-05-15 15:20; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-15 15:20; UTC

Rinkos pokalbiai

Silver Plunges on Inflation Worries -- Market Talk

2026-05-15 15:20; UTC

Uždarbis

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

2026-05-15 14:33; UTC

Rinkos pokalbiai

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

16.92% į viršų

12 mėnesių prognozė

Vidutinis 17 USD 16.92%

Aukščiausias 21 USD

Žemiausias 14 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.